Immix Biopharma Announces Complete Response In 9th Relapsed/Refractory AL Amyloidosis Patient In NXC-201 Clinical Trial At IMS 20th Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma has announced a complete response in the 9th relapsed/refractory AL Amyloidosis patient in the NXC-201 clinical trial. The company plans to submit a BLA for FDA approval in AL Amyloidosis once 40 patients are treated with NXC-201. The expected primary endpoint for NXC-201 in relapsed/refractory AL Amyloidosis is the overall response rate.
October 03, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's successful clinical trial results for NXC-201 could potentially lead to FDA approval, which would likely have a positive impact on the company's stock.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. If Immix Biopharma's NXC-201 receives FDA approval, it could significantly increase the company's revenue, further boosting the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100